Jove
Visualize
Contact Us

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

310
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
310
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

337
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
337
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

264
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
264
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

271
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
271
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

236
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

267
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
267

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Balancing Risk and Hope: Insights Into Pregnancy Outcomes in Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same author

Growing with the patient: toward a lifespan risk score for pediatric pulmonary hypertension.

Revista espanola de cardiologia (English ed.)·2026
Same author

Chronic Thromboembolic Pulmonary Hypertension Incidence, Post-pulmonary Embolism Syndrome and Possible Role of Transcatheter Therapy in Prevention.

Interventional cardiology (London, England)·2026
Same author

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies).

Drugs - real world outcomes·2026
Same author

Transcatheter interventions in adult patients with transposition of the great arteries.

Cardiovascular revascularization medicine : including molecular interventions·2025
Same author

Chronic Thromboembolic Pulmonary Disease With Exercise Pulmonary Hypertension: A Noninvasive Model to Predict Exercise Hemodynamics.

Chest·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 30, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.3K

Pulmonary arterial hypertension.

Raquel Luna-López1, Alicia Ruiz Martín1, Pilar Escribano Subías1

  • 1Unidad de Hipertensión Pulmonar, Servicio de Cardiología, Hospital General Universitario 12 de Octubre, Madrid, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Instituto de Investigación Hospital 12 de Octubre, Madrid, España.

Medicina Clinica
|March 13, 2022
PubMed
Summary

Pulmonary arterial hypertension (PAH) is a rare disease causing heart failure. Early diagnosis and new treatments have significantly improved patient prognosis and quality of life.

Keywords:
Estratificación de riesgoHipertensión arterial pulmonarPulmonary arterial hypertensionPulmonary vascular resistancePulmonary vasodilatorsResistencia vascular pulmonarRight ventricleRisk assessmentVasodilatadores pulmonaresVentrículo derecho

More Related Videos

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.2K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K

Related Experiment Videos

Last Updated: Sep 30, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.3K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.2K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K

Area of Science:

  • Cardiology
  • Pulmonology
  • Vascular Biology

Background:

  • Pulmonary arterial hypertension (PAH) involves arterial remodeling, increasing vascular resistance and right ventricular afterload, potentially leading to heart failure.
  • Nonspecific symptoms and limited pathology knowledge contribute to delayed diagnosis and poor prognosis in PAH patients.
  • Current guidelines emphasize early differential diagnosis of pulmonary hypertension to guide risk-stratified treatment.

Purpose of the Study:

  • To highlight the importance of early diagnosis and risk stratification in managing Pulmonary Arterial Hypertension (PAH).
  • To discuss the impact of recent advancements in diagnostic processes and targeted therapies for PAH.
  • To review the role of specialized referral centers in improving outcomes for PAH patients.

Main Methods:

  • Review of current literature and clinical guidelines on Pulmonary Arterial Hypertension (PAH).
  • Analysis of diagnostic criteria and risk assessment tools for pulmonary hypertension.
  • Examination of the impact of novel therapeutic strategies and specialized care models on PAH patient outcomes.

Main Results:

  • Improved diagnostic accuracy and earlier detection of PAH are crucial for timely intervention.
  • Emergence of specific PAH treatments has led to better disease management and symptom control.
  • Establishment of specialized PAH referral units has enhanced patient care and improved survival rates.

Conclusions:

  • Optimizing early differential diagnosis is key to initiating appropriate, risk-based treatment for Pulmonary Arterial Hypertension (PAH).
  • Advancements in diagnostics, targeted therapies, and specialized care have significantly improved the prognosis and quality of life for PAH patients.
  • Continued research and multidisciplinary approaches are essential for further enhancing outcomes in PAH management.